Evidence mapPaperPMID 34412057Full record

Trial reportDementia and geriatric cognitive disorders2021

Legacy of a 10-Year Multidomain Lifestyle Intervention on the Cognitive Trajectories of Individuals with Overweight/Obesity and Type 2 Diabetes Mellitus.

Kathleen M Hayden, Rebecca H Neiberg, Joni K Evans, José A Luchsinger, Owen Carmichael, Gareth R Dutton, Karen C Johnson, Steven E Kahn, Stephen R Rapp, Sevil Yasar and 2 more

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in Dementia and geriatric cognitive disorders, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Article
  8. Review
  9. Vascular cognitive impairment and dementia: Mechanisms, treatment, and future directions.International journal of stroke : official journal of the International Stroke Society · 2024
    Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Kathleen M HaydenDepartment of Social Sciences and Health Policy, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.
Rebecca H NeibergDepartment of Biostatistics and Data Science, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.
Joni K EvansDepartment of Biostatistics and Data Science, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.
José A LuchsingerDepartments of Medicine and Epidemiology, Columbia University Irving Medical Center, New York, New York, USA.
Owen CarmichaelBiomedical Imaging Center, Pennington Biomedical Research Center, Baton Rouge, Louisiana, USA.
Gareth R DuttonDivision of Preventive Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Karen C JohnsonDepartment of Preventive Medicine, University of Tennessee Health Science Center, Memphis, Tennessee, USA.
Steven E KahnDivision of Metabolism, Endocrinology, and Nutrition, VA Puget Sound Health Care System and University of Washington, Seattle, Washington, USA.
Stephen R RappDepartment of Social Sciences and Health Policy, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.
Sevil YasarDepartment of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.
Mark A EspelandDepartment of Biostatistics and Data Science, Wake Forest School of Medicine, Winston-Salem, North Carolina, USA.
Action for Health in Diabetes (Look AHEAD) Research Group

Funding

WITHIN SUBJ VARIABILITY IN MEASUREMENTS DRUG METABOL ENZYMES IN HLTY SUBJM01RR000056 · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · 1985 to 2005
$27.6M
Metformin in Alzheimer's dementia Prevention (MAP)R01AG062624 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · 2023 to 2025
$22.5M
HEALTH OUTCOMES OF WEIGHT-LOSS: DATA COORDINATING CENTERU01DK057136 · WAKE FOREST UNIVERSITY HEALTH SCIENCES · 1999 to 2005
$18.5M
ZOLEDRONATE VS AREDIA IN MULTIPLE MYELOMA/BREAST CANCER W /BONE DISORDERSM01RR001346 · UNIVERSITY OF TEXAS HLTH SCI CTR SAN ANT · 1985 to 2005
$16.1M
Clinical Center for Look AHEAD: Health in DiabetesU01DK057178 · ST. LUKE'S-ROOSEVELT INST FOR HLTH SCIS · 1999 to 2005
$9.3M
Clinical Center for Look AHEAD: Health in DiabetesU01DK057151 · UNIVERSITY OF COLORADO DENVER · 1999 to 2005
$8.4M
STUDY OF HEALTH OUTCOMES OF WEIGHT-LOSS (SHOW)U01DK057135 · UNIVERSITY OF PENNSYLVANIA · 1999 to 2005
$8.2M
SHOW PROJECTU01DK057154 · MASSACHUSETTS GENERAL HOSPITAL · 1999 to 2005
$8.1M
STUDY OF HEALTH OUTCOMES OF WEIGHT-LOSS (SHOW) TRIALU01DK056992 · MIRIAM HOSPITAL · 1999 to 2005
$8.1M
STUDY OF HEALTH OUTCOMES OF WEIGHT-LOSS (SHOW) TRIALU01DK057177 · BAYLOR COLLEGE OF MEDICINE · 1999 to 2005
$7.7M
Wake Forest Claude D. Pepper OAIC - RenewalP30AG021332 · WAKE FOREST UNIVERSITY HEALTH SCIENCES · 2002 to 2025
$7.7M
STUDY OF HEALTH OUTCOMES OF WEIGHT-LOSS (SHOW)U01DK057002 · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · 1999 to 2005
$7.6M
NCATS NIH HHS UL1 TR002645NCATS NIH HHS UM1 TR004538NCRR NIH HHS M01 RR000056NCRR NIH HHS M01 RR001346NCRR NIH HHS UL1 RR024153NIA NIH HHS P30 AG021332NIA NIH HHS P30 AG049638NIA NIH HHS R01 AG033087NIA NIH HHS R01 AG058571NIA NIH HHS R01 AG062624NIA NIH HHS U01 AG073697NIDDK NIH HHS P30 DK046204NIDDK NIH HHS P30 DK079626NIDDK NIH HHS P30 DK111022NIDDK NIH HHS R01 DK092237NIDDK NIH HHS U01 DK056990NIDDK NIH HHS U01 DK056992NIDDK NIH HHS U01 DK057002NIDDK NIH HHS U01 DK057008NIDDK NIH HHS U01 DK057078NIDDK NIH HHS U01 DK057131NIDDK NIH HHS U01 DK057135NIDDK NIH HHS U01 DK057136NIDDK NIH HHS U01 DK057149NIDDK NIH HHS U01 DK057151NIDDK NIH HHS U01 DK057154NIDDK NIH HHS U01 DK057171NIDDK NIH HHS U01 DK057177NIDDK NIH HHS U01 DK057178NIDDK NIH HHS U01 DK057182NIDDK NIH HHS U01 DK057219NIGMS NIH HHS U54 GM104940
6 · The paper itself

Abstract

introductionWeight loss and increased physical activity interventions are commonly recommended for individuals with type 2 diabetes (T2D) and overweight or obesity. We examined the impact of randomization to an intensive lifestyle intervention (ILI) on trajectories of cognitive function over 10 years in a cohort of participants in a randomized clinical trial who had T2D and overweight/obesity at baseline.

methodsParticipants aged 45-76 years were enrolled in 2001-2004 and were randomized to the ILI or a diabetes support and education (DSE) condition. Cognitive function was assessed in 3,938 participants at up to 4 time points 8-18 years after randomization. General linear mixed effects models examined cognitive trajectories over time. Subgroup analyses focused on sex, individuals with baseline body mass index >30, those carrying the APOE ε4 allele, and those with a baseline history of cardiovascular disease (CVD).

resultsOverall, there were no differences in the rate of cognitive decline by intervention arm. Subgroup analyses showed that participants who had a baseline history of CVD and were randomized to the ILI arm of the study performed significantly worse on the Stroop Color Word Test than those in the DSE arm. DISCUSSION/

conclusionsThe ILI did not result in preserved cognitive function or slower rates of cognitive decline in this cohort of individuals who had T2D and were overweight or obese at baseline.

Indexed as

Diabetes Mellitus, Type 2OverweightCognitionHumansLife StyleObesityClinical trialCognitive declineExecutive functionObesityOverweightType 2 diabetes

Identifiers

PMID34412057
PMCPMC8530880

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.